(RTTNews) - Biotechnology company Oncolytics Biotech Inc. said Monday it presented positive results from a mid-stage trial of intravenous Reolysin in patients with sarcomas metastatic to the lung at the American Society of Clinical Oncology, or ASCO, annual meeting.
